Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Enlicitide Decanoate→

Enlicitide Decanoate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
2861205-06-1
Molecular formula
C92H129FN14O17
Molecular weight
1722.1 g/mol
Drug class
PCSK9-targeting small interfering RNA (siRNA)RNA interference lipid-lowering therapy
Mechanism of action
A GalNAc-conjugated siRNA targets PCSK9 mRNA in hepatocytes and promotes RISC-mediated degradation, reducing PCSK9 protein and increasing hepatic LDL receptor recycling and LDL-cholesterol clearance.
Indications / reported uses
  • Treatment of adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia, as an adjunct to diet and other lipid-lowering therapies under the US LIPIDRA indication (approved 2026); dosing and label-specific eligibility apply

Sources: US FDA — Novel Drug Approvals for 2026 (enlicitide decanoate) · FDA Drug Trials Snapshot — Enlicitide · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Enlicitide Decanoate Environmental Risk Assessment (ERA) (the Enlicitide Decanoate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.